This is a novel approach among growing interest in integrative approaches for cancer treatment. GO Institute does not support alternative factless therapies and supports research into approaches that may lead to effective therapies, especially where the goal is effective but less toxic treatments. We are a long way off on this, but it is of interest because it shows that out of the box thinking does indeed exist globally in looking for unusual approaches for effective cancer therapies.
“Melbourne, Australia – (BUSINESS WIRE) –Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients with recurrent and metastatic cancer, announced today that the company has received letters of interest to evaluate proenzyme therapy as a method to prevent that Recurrence and metastasis of solid tumors in pancreatic and ovarian cancer. The expressions of interest were made by Dr. Natalia Luque Caro and Fernando Gálvez Montosa, medical oncologists who specialize in pancreatic and ovarian cancer, respectively, from Jaén University Hospital in Granada, Spain. The assessment will most likely be carried out as a separate Phase IIa proof of concept (POC) study with multiple study centers for each target indication.
The expressions of interest were confirmed after a review of the scientific literature by Propanc, which supports the use of proenzymes in pancreatic and ovarian cancer. The Phase IIa POC trials will be conducted after a Phase Ib dose-escalation study planned for 2021 to evaluate the tolerability and activity of proenzyme therapy in patients with advanced solid tumors has been completed at the Peter Mac Cancer Center, Melbourne, Australia.
The company’s novel cell differentiation therapy is based on the science that enzymes stimulate biological responses in the body, particularly enzymes that are secreted by the pancreas. These pancreatic enzymes could be the body’s primary defense against cancer.
To view the company’s Mechanism of Action video on its lead cancer product candidate, PRP, click the link below: http://www.propanc.com/news-media/video